Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study

Song Yao, Lara E. Sucheston, Amy E. Millen, Candace S. Johnson, Donald L. Trump, Mary K. Nesline, Warren Davis, Chi Chen Hong, Susan E. McCann, Helena Hwang, Swati Kulkarni, Stephen B. Edge, Tracey L. O'Connor, Christine B. Ambrosone

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity. Methods and Findings: In case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamin D (25OHD) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (ER), and molecular subtypes defined by ER, progesterone receptor (PR) and HER2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the Roswell Park Cancer Institute from 2003 to 2008. We found that breast cancer cases had significantly lower 25OHD concentrations than controls (adjusted mean, 22.8 versus 26.2 ng/mL, p<0.001). Among premenopausal women, 25OHD concentrations were lower in those with high- versus low-grade tumors, and ER negative versus ER positive tumors (p≤0.03). Levels were lowest among women with triple-negative cancer (17.5 ng/mL), significantly different from those with luminal A cancer (24.5 ng/mL, p = 0.002). In case-control analyses, premenopausal women with 25OHD concentrations above the median had significantly lower odds of having triple-negative cancer (OR = 0.21, 95% CI = 0.08-0.53) than those with levels below the median; and every 10 ng/mL increase in serum 25OHD concentrations was associated with a 64% lower odds of having triple-negative cancer (OR = 0.36, 95% CI = 0.22-0.56). The differential associations by tumor subtypes among premenopausal women were confirmed in case-series analyses. Conclusion: In our analyses, higher serum levels of 25OHD were associated with reduced risk of breast cancer, with associations strongest for high grade, ER negative or triple negative cancers in premenopausal women. With further confirmation in large prospective studies, these findings could warrant vitamin D supplementation for reducing breast cancer risk, particularly those with poor prognostic characteristics among premenopausal women.

Original languageEnglish (US)
Article numbere17251
JournalPLoS One
Volume6
Issue number2
DOIs
StatePublished - 2011

Fingerprint

blood serum
Estrogen Receptors
breast neoplasms
pretreatment
Breast Neoplasms
neoplasms
Vitamin D
Tumors
Serum
Neoplasms
vitamin D
Progesterone Receptors
Blood
25-hydroxyvitamin D
prospective studies
epidemiological studies
Epidemiologic Studies
estrogen receptors
Prospective Studies
blood

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Yao, S., Sucheston, L. E., Millen, A. E., Johnson, C. S., Trump, D. L., Nesline, M. K., ... Ambrosone, C. B. (2011). Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study. PLoS One, 6(2), [e17251]. https://doi.org/10.1371/journal.pone.0017251

Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics : A case-control and a case-series study. / Yao, Song; Sucheston, Lara E.; Millen, Amy E.; Johnson, Candace S.; Trump, Donald L.; Nesline, Mary K.; Davis, Warren; Hong, Chi Chen; McCann, Susan E.; Hwang, Helena; Kulkarni, Swati; Edge, Stephen B.; O'Connor, Tracey L.; Ambrosone, Christine B.

In: PLoS One, Vol. 6, No. 2, e17251, 2011.

Research output: Contribution to journalArticle

Yao, S, Sucheston, LE, Millen, AE, Johnson, CS, Trump, DL, Nesline, MK, Davis, W, Hong, CC, McCann, SE, Hwang, H, Kulkarni, S, Edge, SB, O'Connor, TL & Ambrosone, CB 2011, 'Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study', PLoS One, vol. 6, no. 2, e17251. https://doi.org/10.1371/journal.pone.0017251
Yao, Song ; Sucheston, Lara E. ; Millen, Amy E. ; Johnson, Candace S. ; Trump, Donald L. ; Nesline, Mary K. ; Davis, Warren ; Hong, Chi Chen ; McCann, Susan E. ; Hwang, Helena ; Kulkarni, Swati ; Edge, Stephen B. ; O'Connor, Tracey L. ; Ambrosone, Christine B. / Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics : A case-control and a case-series study. In: PLoS One. 2011 ; Vol. 6, No. 2.
@article{322683286ff1468d8859668bc6619b1e,
title = "Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study",
abstract = "Background: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity. Methods and Findings: In case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamin D (25OHD) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (ER), and molecular subtypes defined by ER, progesterone receptor (PR) and HER2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the Roswell Park Cancer Institute from 2003 to 2008. We found that breast cancer cases had significantly lower 25OHD concentrations than controls (adjusted mean, 22.8 versus 26.2 ng/mL, p<0.001). Among premenopausal women, 25OHD concentrations were lower in those with high- versus low-grade tumors, and ER negative versus ER positive tumors (p≤0.03). Levels were lowest among women with triple-negative cancer (17.5 ng/mL), significantly different from those with luminal A cancer (24.5 ng/mL, p = 0.002). In case-control analyses, premenopausal women with 25OHD concentrations above the median had significantly lower odds of having triple-negative cancer (OR = 0.21, 95{\%} CI = 0.08-0.53) than those with levels below the median; and every 10 ng/mL increase in serum 25OHD concentrations was associated with a 64{\%} lower odds of having triple-negative cancer (OR = 0.36, 95{\%} CI = 0.22-0.56). The differential associations by tumor subtypes among premenopausal women were confirmed in case-series analyses. Conclusion: In our analyses, higher serum levels of 25OHD were associated with reduced risk of breast cancer, with associations strongest for high grade, ER negative or triple negative cancers in premenopausal women. With further confirmation in large prospective studies, these findings could warrant vitamin D supplementation for reducing breast cancer risk, particularly those with poor prognostic characteristics among premenopausal women.",
author = "Song Yao and Sucheston, {Lara E.} and Millen, {Amy E.} and Johnson, {Candace S.} and Trump, {Donald L.} and Nesline, {Mary K.} and Warren Davis and Hong, {Chi Chen} and McCann, {Susan E.} and Helena Hwang and Swati Kulkarni and Edge, {Stephen B.} and O'Connor, {Tracey L.} and Ambrosone, {Christine B.}",
year = "2011",
doi = "10.1371/journal.pone.0017251",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics

T2 - A case-control and a case-series study

AU - Yao, Song

AU - Sucheston, Lara E.

AU - Millen, Amy E.

AU - Johnson, Candace S.

AU - Trump, Donald L.

AU - Nesline, Mary K.

AU - Davis, Warren

AU - Hong, Chi Chen

AU - McCann, Susan E.

AU - Hwang, Helena

AU - Kulkarni, Swati

AU - Edge, Stephen B.

AU - O'Connor, Tracey L.

AU - Ambrosone, Christine B.

PY - 2011

Y1 - 2011

N2 - Background: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity. Methods and Findings: In case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamin D (25OHD) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (ER), and molecular subtypes defined by ER, progesterone receptor (PR) and HER2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the Roswell Park Cancer Institute from 2003 to 2008. We found that breast cancer cases had significantly lower 25OHD concentrations than controls (adjusted mean, 22.8 versus 26.2 ng/mL, p<0.001). Among premenopausal women, 25OHD concentrations were lower in those with high- versus low-grade tumors, and ER negative versus ER positive tumors (p≤0.03). Levels were lowest among women with triple-negative cancer (17.5 ng/mL), significantly different from those with luminal A cancer (24.5 ng/mL, p = 0.002). In case-control analyses, premenopausal women with 25OHD concentrations above the median had significantly lower odds of having triple-negative cancer (OR = 0.21, 95% CI = 0.08-0.53) than those with levels below the median; and every 10 ng/mL increase in serum 25OHD concentrations was associated with a 64% lower odds of having triple-negative cancer (OR = 0.36, 95% CI = 0.22-0.56). The differential associations by tumor subtypes among premenopausal women were confirmed in case-series analyses. Conclusion: In our analyses, higher serum levels of 25OHD were associated with reduced risk of breast cancer, with associations strongest for high grade, ER negative or triple negative cancers in premenopausal women. With further confirmation in large prospective studies, these findings could warrant vitamin D supplementation for reducing breast cancer risk, particularly those with poor prognostic characteristics among premenopausal women.

AB - Background: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity. Methods and Findings: In case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamin D (25OHD) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (ER), and molecular subtypes defined by ER, progesterone receptor (PR) and HER2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the Roswell Park Cancer Institute from 2003 to 2008. We found that breast cancer cases had significantly lower 25OHD concentrations than controls (adjusted mean, 22.8 versus 26.2 ng/mL, p<0.001). Among premenopausal women, 25OHD concentrations were lower in those with high- versus low-grade tumors, and ER negative versus ER positive tumors (p≤0.03). Levels were lowest among women with triple-negative cancer (17.5 ng/mL), significantly different from those with luminal A cancer (24.5 ng/mL, p = 0.002). In case-control analyses, premenopausal women with 25OHD concentrations above the median had significantly lower odds of having triple-negative cancer (OR = 0.21, 95% CI = 0.08-0.53) than those with levels below the median; and every 10 ng/mL increase in serum 25OHD concentrations was associated with a 64% lower odds of having triple-negative cancer (OR = 0.36, 95% CI = 0.22-0.56). The differential associations by tumor subtypes among premenopausal women were confirmed in case-series analyses. Conclusion: In our analyses, higher serum levels of 25OHD were associated with reduced risk of breast cancer, with associations strongest for high grade, ER negative or triple negative cancers in premenopausal women. With further confirmation in large prospective studies, these findings could warrant vitamin D supplementation for reducing breast cancer risk, particularly those with poor prognostic characteristics among premenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=79952207467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952207467&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0017251

DO - 10.1371/journal.pone.0017251

M3 - Article

C2 - 21386992

AN - SCOPUS:79952207467

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e17251

ER -